Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1001-1020 of 1,738 trials

Multifocal Motor Neuropathy: DNTH103 Treatment Study

We are testing a new treatment, DNTH103, for adults with multifocal motor neuropathy to see if it improves muscle strength and quality of life. The study will also check its safety compared to a placebo.

Multifocal Motor Neuropathy1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Venous Ulcers: Stem Cell Treatment Study

We are testing a new treatment using adipose tissue stem cells for people with venous ulcers in their lower limbs. The study aims to see if this treatment helps wounds heal faster and improves quality of life.

Venous Ulcer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyInternal Medicine

Weight Loss in HIV: Semaglutide Study

We are investigating whether the medication semaglutide can help people living with HIV and obesity lose more weight when combined with diet and exercise. The study also looks at its effects on inflammation and overall health.

HIV and Obesity6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyInfectious Diseases

RSV Vaccine Study for Immunocompromised Adults

We are studying how well the RSV vaccine works and its safety in immunocompromised patients aged 18 and older. This includes comparing the immune response after one and two doses of the vaccine.

Respiratory Syncytial Virus (RSV)1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementInfectious DiseasesInternal MedicinePulmonology

Autoimmune Hemolytic Anemia: Anticoagulation Study

We are testing whether prolonged anticoagulation therapy can help prevent blood clots in patients with autoimmune hemolytic anemia. This study will also look at how well patients tolerate the treatment and the timing of any clotting events.

Autoimmune Hemolytic Anemia>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInternal Medicine

Lanreotide and Metformin for Advanced Carcinoids

We are studying the safety of a new treatment combining Lanreotide and Metformin for patients with advanced gastrointestinal or lung carcinoids. This trial aims to understand how well this combination works and its effects on symptoms.

Advanced Progressive Gastro-Intestinal or Lung Carcinoids>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Fungal Nail Infection: MOB015B Solution for Kids

We are studying a new topical solution for treating mild to moderate fungal infections of the nail in children aged 6 to 17. The goal is to see how well it works and how safe it is.

Distal Subungual Onychomycosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyInfectious DiseasesPediatrics

Chemotherapy for Standard Risk Adult Medulloblastomas

We are studying the effects of chemotherapy on adults diagnosed with standard risk medulloblastomas. This trial aims to understand how well this treatment works for this specific group.

MedulloblastomaEfficacy phase (II)Oncology

Peripheral T-Cell Lymphoma: Lacutamab with GemOx

We are studying a new treatment combining Lacutamab with GemOx for patients with relapsed or refractory peripheral T-cell lymphoma. The trial aims to evaluate its effectiveness and safety compared to GemOx alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Gastric Cancer: [18F]AlF-FAPI-74 PET/CT Study

We are testing a new imaging method to improve the staging of advanced gastric cancer. This study aims to see if it can reduce the need for invasive procedures while providing accurate diagnostic information.

Advanced Gastric CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal MedicineOncology

RSV Vaccination in Stem Cell Transplant Recipients

We are studying two RSV vaccines to see how well they work in patients who have received stem cell transplants. The goal is to understand their immune response and effectiveness compared to healthy individuals.

Allogeneic Hematopoietic Stem Cell Transplantation≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesInternal Medicine

Urethral Stenosis: Innovative Fat Injection Treatment

We are studying the safety and potential benefits of injecting fat-derived cells for men with recurrent urethral stenosis after surgery. This trial aims to see if this treatment can improve symptoms and reduce the need for further procedures.

Urethral Stenosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesUrology

Relapsed or Refractory PCNSL: Emavusertib Study

We are studying the safety and effectiveness of a new oral medication, emavusertib, for patients with relapsed or refractory primary central nervous system lymphoma. This trial also explores its use alongside another treatment, ibrutinib.

Hematological MalignancyPrimary Central Nervous System Lymphoma (PCNSL)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Early-Stage Colon Cancer: NICHE Trial for Immunotherapy

We are studying a new immunotherapy treatment for patients with early-stage colon cancer to see if it can reduce tumors before surgery. The trial also aims to identify biomarkers that may help tailor treatments and improve patient outcomes.

Colon or Rectosigmoid Adenocarcinoma≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Lupus Nephritis: KYV-101 CAR T-Cell Therapy

We are testing a new immune cell therapy for individuals with refractory lupus nephritis. The goal is to see if it can improve kidney function in patients who have not responded to other treatments.

Lupus Nephritis>2 yearsSafety phase (I)Efficacy phase (II)NephrologyRheumatology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Type 1 Diabetes: Diamyd® Treatment Study

We are evaluating the safety and feasibility of Diamyd® injections in young people at risk for Type 1 diabetes. This study looks at how the treatment affects their immune system and progression of the disease.

Type 1 Diabetes1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyPediatrics

Telmisartan for Portal Hypertension in Liver Disease

We are studying whether telmisartan can lower liver pressure in patients with advanced chronic liver disease and portal hypertension. This trial will also assess its safety and impact on quality of life.

Compensated Advanced Chronic Liver DiseasePortal Hypertension3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteHepatologyInternal Medicine

Norfloxacin for Portal Hypertension in Decompensated Cirrhosis

We are studying whether norfloxacin can lower portal hypertension in patients with decompensated cirrhosis. The trial also looks at its effects on liver-related complications and overall patient well-being.

Portal HypertensionDecompensated Cirrhosis3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesGastroenterologyHepatology

Portosinusoidal Vascular Disorder: Edoxaban Study

We are studying the safety of edoxaban in patients with Portosinusoidal Vascular Disorder. The trial also explores its potential to prevent blood clots and improve quality of life.

Porto-Sinusoidal Vascular Disorder>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteCardiology